Diprotin A| cas 90614-48-5

Cas No.:	90614-48-5
Chemical Name:	Diprotin A
Synonyms:	L-Isoleucine,L-isoleucyl-L-prolyl-;DiprotinA;H-Ile-Pro-Ile-OH;ILE-PRO-ILE;DIPEPTIDYLPEPTIDASE IV INHIBITOR I;H-ILE-PRO-ILE-OH H2O;ILE-PRO-ILE H2O;Ile-Pro-Ile-OH;L-Ile-L-Pro-L-Ile-OH;L-Isoleucyl-L-prolyl-L-isoleucine;Diprotin A;Ile-Pro-Ile;L-Isoleucine, N-(1-L-isoleucyl-L-prolyl)- (ZCI);L-Isoleucyl-L-prolyl-L-isoleucine (ACI);3: PN: JP2011182742 SEQID: 3 unclaimed protein;JNTMAZFVYNDPLB-PEDHHIEDSA-N;Dipeptidyl peptidase IV inhibitor;isoleucylprolylisoleucine;BSPBio_003515;SMP1_000085;NCGC00178015-01;(2S,3S)-2-((S)-1-((2S,3S)-2-amino-3-methylpentanoyl)pyrrolidine-5-carboxamido)-3-methylpentanoic acid;BDBM50229666;BCBcMAP01_000164;CHEMBL214381;L-Isoleucine, N-(1-L-isoleucyl-L-prolyl)-;CS-0034521;Spectrum2_001480;CHEBI:93213;BRD-K69032158-001-02-2;IPI;AKOS030210980;SCHEMBL6404766;HY-111174;90614-48-5;Spectrum3_001838;DTXSID80920277;(2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid;MFCD00038707;N-(1-L-Isoleucyl-L-prolyl)-L-isoleucine;N-[Hydroxy(1-isoleucylpyrrolidin-2-yl)methylidene]isoleucine;MS-25221;CCG-38872;l-isoleucyl-l-prolyl-l-isoleucine;Diprotin A (H-L-Ile-L-Pro-L-Ile-OH);isoleucyl-prolyl-isoleucine;Diprotin A (Ile-Pro-Ile);(2S,3S)-2-((S)-1-((2S,3S)-2-Amino-3-methylpentanoyl)pyrrolidine-2-carboxamido)-3-methylpentanoic acid;SPBio_001439;KBio3_003020;diprotin A;Q27164930
SMILES:	C(N1CCC[C@H]1C(=O)N[C@H](C(=O)O)[C@@H](C)CC)(=O)[C@@H](N)[C@@H](C)CC
Formula:	C₁₇H₃₁N₃O₄
M.Wt:	341.445744752884
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Diprotin A is a tripeptide inhibitor of dipeptidyl peptidase 4 (DPP-4; IC50 = 1.1 μg/ml).It inhibits degradation of glucagon-like peptide 1 in culture with insulin-secreting BRIN-BD11 rat pancreatic β-cells when used at a concentration of 25 μM.Diprotin A (5 mg/ml) pre-incubation enhances chemotaxis of murine embryonic stem cells towards stromal cell-derived factor-1 (SDF-1/CXCL12) in vitro.Pre-incubation of CD34+ human umbilical cord blood cells with diprotin A (5 mM) prior to injection increases engraftment in NOD/SCID recipient mice.

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.